Left main chronic total occlusion *#as „easy” as can be*

- Arek Pietrasik MD, PhD Department of Cardiology, Medical University of Warsaw
- Gabriele Gasparini MD, PhD Humanitas Research Hospital

Patient characteristics

Male 66 years old







Chief complaints	Past medical history	Diagnostic work up	Pharmacotherapy
Chronic coronary syndrome CCS 2	Past medical history NSTEMI 2010 - CABG - LIMA-LAD, RIMA-RCA PCI RCA (2021) UA 03/2023 - PCI RCA Hypertension	ECHO: EF 50% Hipokinesis of lateral wall	ASA 1x 75 mg Clopidogrel 1x 75 mg Nebivolol 1x 5 mg Ramipril 1x 5 mg Rosuvastatin 1x 20 mg Nitrates on demand

t Coronary Artery 03/2023

Angiographic characteristics

Unstable angina

Femoral approach

Significant lesions in RCA



h - German CTO Expert Forum (live webinar) Case 4

Coronary Artery 03/2023

Angiographic characteristics

LCA Angio

LM:

Patent LIMA-LAD

h - German CTO Expert Forum (live webinar) Case 4

nal mammary arteries grafts 03/2023

RIMA-MG, LIMA-LAD

RIMA-RCA:

Subselective injection

Patent

h - German CTO Expert Forum (live webinar) Case 4

t Coronary Artery PCI 03/2023

Succesfull PCI

PCI RCA OCT-guided

TRA-R

2 EES

Tight Lesion in collateral

h - German CTO Expert Forum (live webinar) Case 4

main CTO

Angiographic characteristics



) score calculations

Entry shape — 1
- Tapered (0)
- Blunt (1)

Calcification — 1
- Absence (0)
- Presence (1)

Bending >45º — 1
- Absence (0)
- Presence (1)

Occlusion length — 0
- < 20 mm (0)
- > 20 mm (1)

Re-try lesion — 0
- No (0)
- Yes (1)



J - CTO

Category of difficulty: Difficult

Probability of crossing in less then 30 min: 22.2%

Total J-CTO score: 3 points

PROGRESS-CTO MACE risk

4.2 %

PROGRESS-CTO Mortality risk

0.9 %

PROGRESS-CTO Perforation risk

*perforation requiring treatment

9.0 %

PROGRESS-CTO Pericardiocentesis risk

only in patients without prior CABG

PROGRESS-CTO Acute MI risk

1.2 %

PROGRESS-CTO German CTO Ex se 4

main CTO PCI

Planned strategy TBD

Planned strategy:

Dual injection

Crossable collaterals

AW

Calcium modifications

main CTO PCI

Dual injection



Planned strategy:

Dual injection

Crossable collaterals

AW

Calcium modification

h - German CTO Expert Forum (live webinar) Case 4

















h - Germ

main CTO PCI

Stents postdilatations



stents

m2

erage

ebinar) Case 4

main CTO PCI

Final effect





h - Germar

main, CTO PCI

Final effect









Two Synergy stents

MSA 9.2 mm2

LM ostial coverage